Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has completed the expansion of two new suites at its biologics drug substance development and manufacturing facility in Madison, Wisconsin, and has now commenced work on customer programs. The expansion has increased the number of manufacturing suites at the site to five, more than doubling its overall CGMP-scale capacity. Catalent first announced the investment to add two new mammalian cell culture suites at the Madison site in January 2019. Each new suite includes a 2×2,000-liter single-use bioreactor
The post Catalent Biologics Completes Madison Facility Expansion to Double Clinical and Commercial Drug Substance Capacity appeared first on Pharma Mirror Magazine.
